Define the Vision, Drive the Culture, and Discover New Methods for Success
Now in it's 18th year, the Fierce Pharma PR & Communications Summit continues to be the premier event dedicated to providing life science communicators with industry updates and best practices for successful communications strategies during today’s complex healthcare environment.
Whether you’re more efficiently communicating your company’s innovative therapies and technologies, pushing the limits to tell a more compelling narrative or building out your personal skill set to bring more to the proverbial table, it’s time to take control.
Meet the 2022 Chairperson
Wendy Lund
Chief Communications Officer
Organon
Wendy Lund has been an integral part of the Fierce Pharma PR & Communications Summit for 16 years serving on the Advisory Board, speaking and most recently serving as Chairperson for our East Coast and West Coast Summit. Come join Wendy and the All-Star lineup of speakers that are scheduled at this year's events!
Featured Sessions from 2022:
- The Evolution of the Corporate Communications Role
- Demystifying the ESG Hype
- Combating Misinformation and Bias in Healthcare Communications
- What can Pharma Learn from Outside Industries
- The Magic of Mentorship: Drive Career Growth, Build a Network, and Gain Valuable Insights
- Improving the Patient Experience with Patient Advocacy
Maximize learning by attending as a group and save 25% or more.
If you plan to send multiple people from your team to the Fierce Pharma PR & Communications Summit, please contact us for custom group pricing.
2022 Registrants of the Fierce Pharma PR & Communications Summit Include Communications Executives from Top Pharmaceutical and Biotech Companies. Below is a Sample of Some of the Companies That Attended:
- AbbVie
- Acorda Therapeutics, Inc.
- Alkermes
- Allstate
- Alnylam Pharmaceuticals
- Amgen
- Arvinas, Inc.
- Astellas Pharma
- Asuragen
- Aztiq
- Bavarian Nordic
- BeiGene
- BI Worldwide
- Biogen
- BioNJ
- bluebird bio
- Boehringer Ingelheim
- Bristol Myers Squibb
- Caladrius Biosciences
- Clover Biopharmaceuticals
- Clyde Group
- CSL Behring
- Cullinan Oncology
- Deerfield Management
- Dicerna/Novo Nordisk
- Endo Pharmaceuticals
- Finn Partners
- Forge Biologics
- FTI Consulting
- Gagen MacDonald
- GCI Health
- Golin Health
- Grand River Aseptic Manufacturing
- GSK
- HDMZ
- Homology Medicines
- Horizon Therapeutics
- Insmed
- Ionis Pharmaceuticals
- Kaléo
- LifeSci Advisors LLC
- LifeSci Communications
- Ligand Pharmaceuticals
- Lyndra Therapeutics
- Marina Maher Communications
- MeiraGTx
- Merck
- Minaris Regenerative Medicine
- Mirati Therapeutics
- Nexus Pharmaceuticals
- Novo Nordisk
- Ocugen
- Organon
- Passage Bio
- Pfizer
- Phizzle
- Boston University College of Communication
- Quest Diagnostics
- Real Chemistry
- Red Havas
- Regeneron
- Roche Diagnostics
- Rutgers University
- RXMosaic
- Sage Therapeutics
- Spark Therapeutics
- Spectrum Science
- Sumitovant Biopharma
- Takeda
- TellMed Strategies
- Teva Pharmaceuticals
- The Female Quotient (TFQ)
- The Harris Poll
- twelvenote
- Venatorx Pharmaceuticals
- Vor Bio
- Weber Shandwick